Summary
Abuse potential refers to the likelihood for a drug to be used in nonmedical situations for its positive psychoactive effects. PRA Health Sciences’ Early Development Services group offers expert services to measure abuse potential of investigational drugs by performing human abuse liability (HAL) studies, which are required for drugs that affect the central nervous system, drugs similar to known drugs with abuse potential, and drugs with positive psychoactive effects. This poster discusses what a HAL study is and the challenges posed to study teams and medical writers by the complexity and unique design of these Phase I clinical trials.
Register to download
Human Abuse Liability Studies: Not Your Traditional Phase I Study
You may also be interested in:
White Paper
Strategies for Accelerating Rare Disease Clinical Development
Rare disease trials differ from those in most other therapeutic areas because the indications are more complex and involve smaller patient…
Poster
Marijuana Effect on Differentiating an Opioid from Placebo During the Discrimination Phase of a Human Abuse Potential Study
Subjects of human abuse potential (HAP) studies must be able to detect liking with the investigational drug. However, many subjects recruited for HAP…
Fact Sheet
Pharmacogenomics in Pain Management
Pharmacogenomics in Pain Management. In the US alone there are an estimated 100 million adults suffering from chronic pain. Pharmacogenomics and…